Trial intelligence / Profile preview

IPT803 in Parkinson's Disease

NCT03407378Phase 2

Key facts

Status: Completed
Start: Jun 2018
Primary completion: Feb 2020
Countries: 3
Sponsor: Cognivia
Modality: Small Molecules

Drugs: IPT803
Conditions: Parkinson's disease (PD)

Overview

Phase 2, randomised, double-blind trial of IPT803 in Parkinson's disease (PD), sponsored by Cognivia. Primary endpoint: Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale Part III at 12 weeks. Started Jun 2018; status: completed.

Design

Study design: RandomizedDouble-blind

Endpoints

Primary

Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale Part III12 weeks

Beyond the preview

Go deeper on NCT03407378.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03407378.